List of Excipients in Branded Drug FEXOFENADINE HCL

Generic Drugs Containing FEXOFENADINE HCL

Company	Ingredient	NDC	Excipient
Walgreens	fexofenadine hcl	0363-6231	AMMONIA
Walgreens	fexofenadine hcl	0363-6231	CELLULOSE, MICROCRYSTALLINE
Walgreens	fexofenadine hcl	0363-6231	CROSCARMELLOSE SODIUM
Walgreens	fexofenadine hcl	0363-6231	D&C RED NO. 33

What are the Most Frequently-Used Excipients in FEXOFENADINE HCL?

# Of NDCs	Excipient
2	AMMONIA
24	ANHYDROUS LACTOSE
41	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Last updated: August 25, 2026

Fexofenadine hydrochloride is a mature, largely commoditized antihistamine with limited active-ingredient patent protection. The strongest commercial opportunities are formulation-led: pediatric liquids, orally disintegrating tablets, chewables, sugar-free products, preservative-free unit doses, and differentiated combination products. Excipient selection must account for taste, suspension stability, rapid disintegration, moisture control, and potential effects on intestinal uptake.

Fexofenadine HCl Excipient Strategy and Commercial Opportunities

What is the commercial position of fexofenadine hydrochloride?

Fexofenadine hydrochloride is a second-generation H1 antihistamine marketed globally for allergic rhinitis and chronic idiopathic urticaria. The originator product, Allegra, was developed by Hoechst Marion Roussel and later commercialized by Aventis and Sanofi. The product transitioned from prescription to over-the-counter status in the United States in 1997.[1]

U.S. dosage forms include immediate-release tablets, orally disintegrating tablets, oral suspension, and combination products containing pseudoephedrine. Generic fexofenadine products are widely available, and the active ingredient is no longer protected by a commercially meaningful compound patent barrier.

Attribute	Commercial assessment
Active ingredient	Fexofenadine hydrochloride
Therapeutic class	Second-generation antihistamine
Main indications	Seasonal allergic rhinitis and chronic idiopathic urticaria
Common strengths	30 mg, 60 mg, 180 mg
Key dosage forms	Tablets, orally disintegrating tablets, oral suspension, combination tablets
Prescription status	OTC in the United States for major consumer products
Generic competition	Extensive
Current value driver	Brand, channel, convenience, taste, pediatric suitability, and price
Primary formulation risk	Variable absorption and poor consumer acceptance caused by taste or dosing inconvenience

The market is therefore suitable for formulation development, private-label products, contract manufacturing, and regional licensing rather than new-molecule exclusivity.

What excipients are used in commercial fexofenadine tablets?

Commercial immediate-release tablets use conventional excipients designed for mechanical strength, rapid disintegration, lubrication, and manufacturability. Allegra tablet labels identify combinations including microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate.[2]

A representative immediate-release excipient system is:

Functional purpose	Candidate excipients
Diluent and compactability	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate
Binder	Pregelatinized starch, povidone, low-substituted hydroxypropyl cellulose
Lubrication	Magnesium stearate, sodium stearyl fumarate
Glidant	Colloidal silicon dioxide
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides
Taste masking	Ion-exchange resin, polymer coating, lipid coating, sweetener-flavor system

The preferred excipient strategy depends on the product objective. A low-cost generic tablet favors standard cellulose-starch systems. A premium OTC product may justify mannitol-based mouthfeel, reduced tablet size, improved swallowability, and a more robust coating.

Fexofenadine hydrochloride is relatively polar and has a pronounced medicinal taste. Taste control is more important in orally disintegrating, chewable, and liquid products than in conventional swallowed tablets.

Which excipients are best for fexofenadine orally disintegrating tablets?

Orally disintegrating tablets have the clearest formulation opportunity because they can improve convenience without requiring a new active ingredient. Suitable systems commonly include mannitol as a diluent, crospovidone or croscarmellose sodium as a superdisintegrant, low levels of colloidal silicon dioxide, and a direct-compression binder.

Mannitol is commercially attractive because it provides a cooling sensation and improved mouthfeel. It can also support low-moisture processing. Crospovidone often supports rapid water uptake without excessive gel formation. Excessive magnesium stearate can slow wetting and disintegration, particularly when over-lubrication occurs.

Key development targets include:

• Disintegration in approximately 30 seconds or less.
• Adequate tensile strength for packaging and transport.
• Low friability.
• Reduced bitter or medicinal aftertaste.
• Moisture protection through high-barrier blister packaging.
• Consistent dose uniformity at 30 mg and 60 mg strengths.

A formulation that disintegrates rapidly but releases an intense bitter taste may fail commercially. Taste masking should be evaluated through a combination of in vitro dissolution, electronic taste analysis, and controlled human sensory testing.

What excipients are appropriate for fexofenadine oral suspension?

Oral suspension is a high-value dosage form for pediatric and geriatric use. The formulation must maintain dose uniformity after storage, tolerate repeated shaking, minimize sedimentation, and preserve acceptable taste.

Potential suspension excipients include:

Function	Candidate excipients
Suspending agent	Xanthan gum, hypromellose, microcrystalline cellulose-carboxymethylcellulose blends
Wetting agent	Polysorbate 80, poloxamer, controlled levels of surfactant
Buffer	Citrate or phosphate systems, subject to compatibility and taste
Sweetener	Sucrose, sorbitol, sucralose, acesulfame potassium
Flavor	Fruit flavors selected for pediatric masking
Preservative	Potassium sorbate, sodium benzoate, or alternative validated systems
Viscosity modifier	Glycerin, sorbitol, hypromellose
Chelator	Disodium edetate where justified by stability data

The commercial design space divides into four products:

1. A low-cost, sugar-containing suspension for mass-market OTC use.
2. A sugar-free product for consumers managing sugar intake.
3. A preservative-reduced or preservative-free unit-dose product.
4. A concentrated formulation that reduces bottle size and shipping cost.

Preservative selection requires pH control and microbial challenge testing. A product with a weak preservative system may face larger regulatory and manufacturing risks than a conventional preserved suspension. Packaging is also material: single-dose sachets or stick packs can reduce contamination during repeated use but may raise filling and packaging costs.

How do excipients affect fexofenadine absorption?

Fexofenadine exposure is sensitive to intestinal transport and coadministration conditions. Apple, grapefruit, and orange juices can reduce exposure, and aluminum- or magnesium-containing antacids can reduce absorption when administered closely in time.[1,3]

The primary excipient implications are:

• Avoid unnecessary use of polyvalent metal salts.
• Evaluate surfactants for effects on permeability and transporter activity.
• Control formulation pH and ionic strength.
• Assess excipient effects using comparative dissolution and pharmacokinetic studies.
• Avoid assuming that rapid dissolution guarantees bioequivalence.
• Evaluate liquid and ODT products separately from conventional tablets.

Fexofenadine is transported by intestinal uptake and efflux systems, including OATP-related pathways. Excipients that alter luminal solubilization, membrane interaction, or transporter activity can affect exposure even when the active ingredient remains chemically unchanged.[3,4]

The risk is highest for novel excipient combinations, high surfactant concentrations, lipid-based systems, and products intended to improve apparent bioavailability. A formulation that materially increases exposure may create a regulatory issue rather than a commercial advantage.

What formulation patents protect fexofenadine products?

The original fexofenadine compound and formulation patent estate is historical. U.S. Patent No. 5,375,693 covered fexofenadine-related subject matter and expired after the statutory patent term, subject to applicable patent-term adjustments and extensions.[5] The Allegra product also had related patents and regulatory exclusivity periods, but those protections no longer prevent ordinary generic entry.

Current product differentiation is more likely to depend on:

• New excipient ratios.
• Taste-masked particles.
• Modified particle size or granulation.
• ODT architecture.
• Stable pediatric suspension systems.
• Preservative-free packaging.
• Combination products.
• Manufacturing process controls.
• Device and packaging claims.

A formulation patent must show more than routine substitution of one tablet excipient for another. Stronger claims typically require a defined composition linked to a measurable technical effect, such as improved stability, reduced bitterness, faster disintegration, lower friability, or reduced dose segregation.

When does fexofenadine lose exclusivity?

Fexofenadine has already lost effective U.S. market exclusivity. Generic products have been approved for multiple strengths and dosage forms, and the market does not depend on a pending first generic launch.

Exclusivity element	Status
Compound patent	Expired
Core Allegra exclusivity	Expired
Generic entry	Established
OTC switch protection	Expired
Orange Book strategy	Relevant mainly to listed branded and combination products
Biosimilar exclusivity	Not applicable
Current competitive moat	Brand recognition, retail placement, pricing, formulation convenience

Paragraph IV challenges were commercially relevant during the historical generic-entry period. They are not the principal risk category for current fexofenadine development. For a new entrant, the relevant legal analysis concerns freedom to operate around later formulation, process, combination, packaging, and trademark rights.

What is the Orange Book status of fexofenadine products?

The FDA Orange Book is relevant to approved prescription and certain listed products, but the strategic significance of Orange Book listings is limited for a mature OTC antihistamine. The principal active-ingredient patents that supported Allegra exclusivity have expired. New developers should distinguish among:

• Expired compound patents.
• Expired formulation patents.
• Any surviving patents covering combination products.
• Non-patent regulatory exclusivity.
• Trademark and trade-dress rights.
• Manufacturing know-how that is not publicly disclosed.

An ANDA or other abbreviated pathway must still meet applicable requirements for strength, dosage form, quality, labeling, and bioequivalence. Patent expiry does not eliminate formulation development work.

Which companies are challenging fexofenadine, and what is the litigation status?

Generic manufacturers have challenged and entered the fexofenadine market through the ordinary abbreviated-approval pathway. The major historical disputes concerned Allegra patent rights and generic timing. There is no widely recognized current patent litigation barrier comparable to an active, market-blocking compound patent.

For new products, litigation exposure is more likely to arise from:

• A later-filed formulation patent.
• A fexofenadine-pseudoephedrine combination.
• A branded ODT or suspension platform.
• Trade dress or trademark claims.
• Contract manufacturing and confidential-information disputes.

Settlement agreements from historical generic litigation may have affected launch timing, but they are no longer the principal commercial determinant for standard fexofenadine products.

What commercial opportunities exist for fexofenadine excipients?

Pediatric and family formulations

Pediatric suspension remains one of the most defensible formulation segments. Commercial value comes from dosing accuracy, taste, reduced sedimentation, easy pouring, and stable storage after opening. An oral syringe-compatible bottle and a low-foam suspension can provide practical differentiation.

Sugar-free and clean-label products

Sugar-free formulations using sorbitol, xylitol, sucralose, or high-intensity sweeteners can target diabetic consumers and adult users who prefer reduced sugar. Polyol levels require gastrointestinal tolerability testing and careful labeling.

Orally disintegrating and chewable products

ODTs and chewables can support premium pricing and private-label retail placement. Taste masking, tablet robustness, and moisture protection are the key technical barriers.

Preservative-free unit doses

Unit-dose liquids and powders can reduce contamination risk and support travel, institutional, and pediatric use. The commercial tradeoff is higher packaging cost and more complex filling operations.

Combination products

Fexofenadine-pseudoephedrine products combine antihistamine treatment with nasal decongestion. Opportunities include smaller tablets, once-daily dosing, improved coating, and reduced stimulant-related consumer complaints. Combination products carry more regulatory, labeling, and pharmacovigilance complexity than single-ingredient products.

Regional licensing and contract development

Because the active ingredient is widely available, licensing value is concentrated in formulation platforms, regulatory files, manufacturing capacity, and distribution access. A company with a validated pediatric suspension or taste-masked ODT can license the product regionally without owning the active pharmaceutical ingredient.

How strong is the fexofenadine formulation patent estate?

The estate is weak at the active-ingredient level and potentially moderate at the formulation level. Standard tablets based on routine excipients are difficult to protect broadly. Narrow patents may still be commercially useful when they cover a reproducible technical result and are supported by comparative data.

Patent area	Relative strength
Fexofenadine molecule	Low; historical protection expired
Conventional immediate-release tablet	Low
Basic ODT composition	Low to moderate
Taste-masked ODT with defined performance	Moderate
Pediatric suspension with stability and dose-uniformity data	Moderate
Novel combination product	Moderate, depending on claim scope
Manufacturing process	Moderate if process-specific and difficult to design around
Packaging and dosing system	Low to moderate
Trade secret manufacturing controls	Commercially useful but not patent exclusivity

Geographic coverage should be assessed country by country. Patent expiry, regulatory approval, OTC status, and generic substitution rules differ across the United States, European Union, Japan, China, India, and emerging markets.

What generic launch risks exist for new fexofenadine products?

A standard generic tablet has low launch risk but limited margin. A differentiated formulation has greater upside and greater development risk.

The main risks are:

• Failure to demonstrate bioequivalence.
• Taste masking that delays dissolution.
• Suspension sedimentation or dose nonuniformity.
• Moisture-related ODT degradation.
• Preservative failure.
• Excipient availability or supplier changes.
• Consumer rejection of aftertaste.
• Retail price compression.
• Combination-product regulatory complexity.
• Infringement of later formulation or packaging claims.

The most attractive launch sequence is usually a conventional tablet for volume, followed by an ODT, chewable, or pediatric suspension for margin. A formulation patent should be filed before public disclosure, while process controls and sensory data should be retained as confidential know-how.

Key Takeaways

• Fexofenadine HCl is a mature antihistamine with expired core patent protection and extensive generic competition.
• Excipient strategy, not molecule exclusivity, determines commercial differentiation.
• ODTs, chewables, pediatric suspensions, sugar-free products, and unit-dose formats offer the clearest opportunities.
• Mannitol, crospovidone, croscarmellose sodium, microcrystalline cellulose, hypromellose, xanthan gum, and validated sweetener systems are relevant development tools.
• Absorption must be evaluated carefully because juice and mineral interactions are clinically relevant.
• Broad claims covering routine excipient substitutions are weak; claims tied to demonstrated taste, stability, disintegration, or dose-uniformity benefits are stronger.
• Biosimilar risk does not apply because fexofenadine is a small-molecule drug.
• Commercial success depends on retail positioning, sensory performance, pediatric usability, manufacturing cost, and regulatory execution.

FAQs

Can fexofenadine HCl be formulated as a sustained-release product?

Yes, but the commercial case is limited because once-daily immediate-release strengths already exist. A sustained-release product would require clear exposure, efficacy, safety, and adherence benefits.

Which excipient is best for masking the bitterness of fexofenadine?

No single excipient is universally best. Ion-exchange resins, polymer coatings, lipid barriers, and sweetener-flavor systems should be compared using dissolution and sensory data.

Is fexofenadine HCl suitable for a preservative-free liquid?

Yes. A preservative-free liquid is more practical in unit-dose packaging or a dry powder for reconstitution than in a multidose bottle.

Are fexofenadine products eligible for biosimilar development?

No. Fexofenadine is a chemically synthesized small molecule. Generic drug pathways, not biosimilar pathways, are relevant.

What is the most defensible fexofenadine formulation opportunity?

A taste-masked pediatric suspension or ODT with demonstrated stability, dose uniformity, rapid disintegration, and a differentiated packaging system is more defensible than a conventional tablet using standard excipients.

References

1. U.S. Food and Drug Administration. (2023). Allegra Allergy fexofenadine hydrochloride tablet, film coated: Prescribing information. FDA/DailyMed.

2. DailyMed. (2024). Fexofenadine hydrochloride tablet: Inactive ingredients and labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2023). Allegra oral suspension and tablet labeling. FDA/DailyMed.

4. Akazawa, T., et al. (2012). Effects of fruit juices on the pharmacokinetics of fexofenadine. Clinical Pharmacology and Therapeutics, relevant transporter-interaction literature.

5. United States Patent and Trademark Office. (1995). U.S. Patent No. 5,375,693, fexofenadine-related antihistamine compounds and pharmaceutical compositions. USPTO.